What Визарсин Treats: Main Uses and Benefits

Визарсин (Sildenafil) is commonly used to manage the functional condition of Erectile Dysfunction (ED), which is the consistent or recurrent inability to achieve or maintain a penile erection adequate for satisfactory sexual performance. This is the primary therapeutic domain of Sildenafil.

The medication is applied across domains where additional symptomatic support is needed, helping address symptom clusters related to impaired erection achievement and impaired erection maintenance. This supportive relief is relevant across various etiologies, including ED linked to age-related vascular changes or conditions like diabetes. The goal of therapy is to assist with maintaining functional stability to support sexual activity, particularly during phases where functional capacity is temporarily compromised.

This medication helps address symptom clusters that interfere with daily functioning and supports patients during episodes of heightened discomfort. It is commonly used to help with symptom management across the spectrum of mild, moderate, or severe ED.

Quick Fact: Relief for Functional Impairment

Aspect	Description
Primary Indication	Erectile Dysfunction (ED)
Symptom Focus	Inability to achieve or maintain erection
Benefit Framing	Supports functional stability
Severity Relevance	Applicable for mild, moderate, or severe ED

Regulatory References

1. NIH MedlinePlus overview of Sildenafil

Official Eligibility Profile: Who Can and Cannot Use Визарсин

Визарсин (Sildenafil) is officially indicated only for adult men (18 years and older) and is not indicated for use by women or the paediatric population.

Absolute Contraindications (Must Not Use)

The medicine is strictly contraindicated and must not be used by patients who are taking nitrates or nitric oxide donors in any form (e.g., for chest pain), or the guanylate cyclase stimulator riociguat, due to the risk of severe blood pressure drop. Use is also forbidden for patients with a known allergy to sildenafil or its excipients.

In addition, the medicine is contraindicated in patients with certain high-risk medical conditions, including:

• A history of vision loss due to Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION).
• Severe cardiovascular disorders (e.g., unstable angina, severe heart failure) where sexual activity is inadvisable.
• A recent history of stroke or myocardial infarction.
• Severe hypotension (blood pressure below 90/50 mmHg).
• Severe hepatic impairment or known hereditary degenerative retinal disorders (e.g., retinitis pigmentosa).

Restricted or Conditional Use

Caution or a lower starting dose (e.g., 25 mg) must be considered for patients with severe renal impairment, mild to moderate hepatic impairment, or for older adult patients (age 65+). Special caution is also advised for patients with anatomical deformation of the penis or conditions that predispose to priapism (e.g., sickle cell anaemia).

Interactions with other medicines and products

The official regulatory labeling for Визарсин (Sildenafil) documents several clinically significant interactions, which are classified based on the resulting safety implication.

Contraindicated Combinations

The product is contraindicated for use with nitric oxide donors (such as organic nitrates or nitrites) in any form. This restriction is due to the risk of severe blood pressure drop (potentiation of hypotensive effects). Co-administration with Guanylate Cyclase (GC) stimulators, such as riociguat, is also contraindicated for the same reason.

Significant Drug Interactions

Interacting Product Category	Implication and Constraint
Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole)	These increase the plasma concentration of Визарсин. For Ritonavir, a maximum dose of 25 mg within 48 hours is officially constrained.
Alpha-blockers	Co-administration may lead to symptomatic low blood pressure (hypotension). Official labeling suggests that patients must be hemodynamically stable on alpha-blocker therapy before initiating Визарсин, and a starting dose of 25 mg is considered.
Moderate-to-Strong CYP3A Inducers (e.g., Bosentan)	These decrease the concentration of Визарсин, which may require dose adjustment when starting or stopping the inducer.
Other PDE5 Inhibitors or treatments for erectile dysfunction	Co-administration is not recommended due to lack of established safety and efficacy data for such combinations.

These constraints are defined in regulatory documents to manage the risk associated with changes in drug exposure or exaggerated pharmacologic effects.

How Визарсин Works: Mechanism of Action

Визарсин's primary biological action is the selective competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5). This targeted molecular interference occurs in tissues where PDE5 is concentrated, such as the smooth muscle cells of the vasculature. Inhibition of the enzyme prevents the hydrolysis (breakdown) of the second messenger molecule cyclic Guanosine Monophosphate (cGMP).

By conserving cGMP, the drug effectively amplifies and prolongs the natural signaling cascade initiated by Nitric Oxide (NO) release, which is the key cellular process for reducing vascular smooth muscle tone. The resulting accumulation of cGMP triggers intracellular processes that lead to the profound vasodilation (widening of arteries) in the targeted tissue. The system-level physiological consequence of this mechanism is a significant increase in localized tissue perfusion (blood flow).

Визарсин (Sildenafil) is administered orally and is intended for intermittent, as-needed use, with the maximum recommended frequency restricted to a single dose once per day. The medicine is supplied as standard film-coated tablets and as orodispersible tablets (Q-tab).

The standard recommended starting dose for adult men is 50 mg, which should be taken approximately one hour prior to anticipated sexual activity. The time window for administration extends from 30 minutes to 4 hours before use. The dose may be adjusted to a minimum of 25 mg or increased up to a maximum recommended dose of 100 mg.

The tablets may be taken with or without food. However, consuming the dose with a high-fat meal may result in a delayed onset of activity. The orodispersible form, a specific instruction for administration, should be placed on the tongue to dissolve without the use of water.

Dosage adjustments apply to certain patient populations. A starting dose of 25 mg is used for individuals with severe renal impairment (Creatinine Clearance < 30 mL/min), those with hepatic impairment, and adults 65 years and older. Furthermore, a restricted maximum dose of 25 mg within a 48-hour period applies when the medicine is co-administered with certain strong CYP3A4 inhibitors.

Research Evidence / Overview of Studies for Визарсин

Evidence for use in Chronic Pain

Визарсин was studied for use in people experiencing chronic pain. The research was evaluated in short-term studies, primarily randomized controlled trials (RCTs), applied in studies examining patient-reported experiences of discomfort. Findings describe patterns observed in the studies over the short follow-up durations, where participants receiving Визарсин was observed in some studies to report patterns related to changes in measured pain scores compared to individuals who received a placebo. Evidence is limited regarding the long-term measurements of these patterns, and durability is not fully established. Data for certain groups remain insufficient.

---

Evidence for use in Spasticity associated with Multiple Sclerosis (MS)

Research examined the administration of Визарсин in individuals with Multiple Sclerosis (MS), which are conditions marked by functional limitations such as spasticity. Studies monitored outcomes related to physical discomfort, often using objective scales. Studies report how symptoms evolved in the observed populations, indicating that some participants showed measurements taken for objective spasticity scores over short intervals. The evidence base is limited because trials focused on near-term observations; persistence of measured patterns over an extended period are not fully established.

---

Evidence for use in Refractory Epilepsy

Визарсин was studied for use as an additional (add-on) therapy for specific, severe epilepsies, notably Dravet Syndrome and Lennox-Gastaut Syndrome. Research evaluated outcomes related to seizure counts in children and adults. Data show patterns related to measurements taken for seizure count in the studied groups compared to the control groups. Studies monitored the occurrence of certain measured events, such as drowsiness and changes in liver enzyme measurements. Long-term effects are not fully established, particularly the sustained patterns on developmental outcomes in pediatric populations. Follow-up durations were limited.

---

What is still uncertain about Визарсин

The evidence base is limited by the modest sample sizes and restricted follow-up periods across all indications. Evidence quality varies across studies, and comparative evidence is lacking against other established therapies. Findings were mixed or inconsistent across study methods, especially concerning patient-reported outcomes like overall quality of life. Research provides context but not individual predictions, and the main uncertainty lies in the lack of data demonstrating sustained patterns and long-term safety profiles across the studied conditions.

Common questions about Визарсин (FAQ)

Q: What research evidence supports the use of Визарсин?

The therapeutic purpose of this medicine, which is to restore or improve erectile function, is supported by clinical trials. These studies assessed the ability of the medication to help men achieve and sustain an erection sufficient for sexual activity. Official product information describes these findings in the pharmacological section of the regulatory documents.

Q: Does the use of Визарсин require any special health checks?

Regulatory documents describe the need for a medical examination before starting treatment. This assessment is required to evaluate the patient's underlying cardiovascular health status and determine if sexual activity itself is advisable. A medical assessment for any potential underlying cardiovascular risk factors is generally described as necessary prior to initiating treatment.

Q: Can Визарсин be used by people with a history of stroke?

Official information states that the medicine is strictly contraindicated (must not be used) in patients with a recent history of stroke or myocardial infarction (heart attack). The determination of 'recent history' is part of the medical assessment conducted by a healthcare professional.

Q: Do men need to be tested for certain conditions before using Визарсин?

A medical assessment for any potential underlying cardiovascular risk factors is described in regulatory documents as necessary prior to initiating treatment. This is necessary because the medicine can affect the vascular system, and certain pre-existing heart conditions make the use of this medicine inadvisable.

Q: Is Визарсин the same as the drug that starts with S?

Визарсин contains the active ingredient Sildenafil, which belongs to the same class of medicine used for this specific purpose of restoring erectile function. As a generic medicine, it is confirmed by regulatory bodies to be chemically identical and bioequivalent to the originator product in its class.

Q: How long does it take for Визарсин to start working?

According to the official pharmacokinetic data, the maximum concentration of the medicine in the blood is typically reached within 30 to 120 minutes after taking the dose. This time frame can vary among individuals and depends on factors like food intake.

Q: Can Визарсин be taken with food or is it better on an empty stomach?

The tablets may be taken with or without food. However, consuming the dose with a high-fat meal is described in official product information as potentially resulting in a delayed onset of the desired activity, meaning it may take longer to feel the effects.

Q: Is Визарсин available over the counter?

No, this medicine is officially classified as a prescription-only medicine in most major regulatory regions. It requires consultation with a healthcare professional before it can be dispensed.

Q: Does taking Визарсин mean I can't drink coffee?

Official regulatory documents do not list common caffeine intake as a contraindicated interaction. However, excessive stimulant intake may intensify common side effects like headaches or changes in heart rate, so caution regarding excessive intake may be noted in some patient information.

Q: Can Визарсин be used by women?

According to the official product information and regulatory documents, the medicine is not indicated for use by women. Its approved use is specifically limited to adult men experiencing difficulty achieving or maintaining an erection.

Q: Is Визарсин safe for older adults (seniors)?

For older adults (aged 65 years and over), a lower starting dose may be considered by a healthcare professional. This adjustment may be considered due to age-related physiological factors, but specific dose changes are not universally required based on age alone.

Q: What is the main difference between Визарсин and other similar medicines?

The active ingredient is classified as a highly selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5). This means its mechanism is specifically targeted to this enzyme over many others in the body, which defines its pharmacological action compared to other chemical classes of drugs.

Q: Do any foods or vitamins interfere with Визарсин?

Regulatory documents advise against co-administration with Grapefruit juice as it may affect the concentration of the medicine in the body. Furthermore, caution is noted regarding use with certain types of vitamins, such as Vitamin K antagonists, in specific patient groups.

Q: Does Визарсин affect blood pressure?

The medicine is a vasodilator, meaning it causes blood vessels to widen, and its primary action can result in a mild to moderate lowering of systemic blood pressure. Due to this effect, it is strictly contraindicated with other drugs that may cause a severe blood pressure drop, such as nitrates.

Q: Is it true that Визарсин only works for a short time?

The medicine and its main active metabolite have an elimination half-life of approximately 4 hours. While this suggests the medicine is eliminated relatively quickly, clinical effects related to its therapeutic purpose are generally observed up to four hours after administration.

Q: What happens if I miss a time when I usually take Визарсин?

The medicine is for intermittent, as-needed use only, with a maximum recommended frequency of one dose per day. Since it is not taken on a daily schedule, there is no dose to 'miss.' It should only be taken when its effect is desired.

Q: Does Визарсин come in different strengths or forms?

The medicine is available in film-coated tablets in various strengths, typically including 25 mg, 50 mg, and 100 mg, and is also offered as an orodispersible tablet form, which dissolves quickly on the tongue.

Q: Is Визарсин considered a controlled substance?

The medicine is classified as a prescription-only drug. However, in major jurisdictions, it is generally not designated as a federally controlled substance like narcotics or certain stimulants.

Q: Is it safe to drive after taking Визарсин?

Official safety information advises that patients should be aware of how they react to the medicine before driving or operating machinery. This caution is due to common reported side effects that include dizziness and temporary visual disturbances.

Q: Can Визарсин be taken at the same time as cold or flu medicine?

Official labeling notes caution regarding use with certain drugs that may affect blood pressure or heart rate, such as sympathomimetic agents commonly found in cold and flu medicines. Patient labeling advises that the ingredients of cold and flu medicines should be reviewed in the context of co-administration with this medicine.

Q: Does alcohol interact with Визарсин?

Official guidance notes that while the consumption of alcohol is not strictly prohibited, drinking excessive amounts of alcohol may impede the ability to achieve an erection. Alcohol can also increase the risk of side effects such as dizziness.

Q: What should I do if I accidentally take more Визарсин than intended?

In studies of doses higher than recommended, adverse events were generally similar to those seen at lower doses, but regulatory data shows that the frequency and severity of these events were increased. Official documents recommend seeking medical guidance if a dose higher than intended is consumed.

Storage and Disposal Requirements

Official regulatory documents mandate specific conditions for the storage of Визарсин (sildenafil) tablets to ensure product stability. The medicine must be stored at a maximum temperature not exceeding 30 C, which corresponds to Controlled Room Temperature [Source: EMA/Sildenafil SmPC].

Mandatory Conditions

Item	Official Requirement
Temperature Range	Typically 20 C to 25 C (68 F to 77 F) [Source: FDA/DailyMed]
Protection	Keep in the original, tightly closed container to protect from moisture and light [Source: MedlinePlus]
Child Safety	Must be kept out of the sight and reach of children [Source: MedlinePlus]

Disposal Protocol

Unused or expired medicinal product must be disposed of in accordance with local requirements for pharmaceutical waste, as directed by regulatory bodies [Source: Sildenafil SmPC]. Disposal into household trash or wastewater should be avoided.